PMCF for a Novel Coated Hip Implant: Is the Plan Sufficient?
A manufacturer has developed a ceramic-on-ceramic total hip replacement with a novel diamond-like carbon coating. The device is Class III under MDR Rule 8 (implantable). The manufacturer has a PMCF plan that consists of a literature review of published ceramic hip studies and a complaint review. It also proposes a 2-year prospective study with 50 patients, with revision rate as the primary endpoint. The device has a 10-year expected lifetime. The notified body's clinical evaluator is concerned that the PMCF plan is not sufficient for a novel implant and that the 2-year study is too short. Tasks: (a) Evaluate the PMCF plan against MDR Annex XIV Part B. (b) What should a PMCF plan include for this device? (c) How should the PSUR and vigilance data feed into the PMCF and risk management?
1. Evaluate the PMCF plan against MDR Annex XIV Part B.
Read the worked answer
The plan does not meet Annex XIV Part B. Part B requires a proactive and systematic PMCF plan with objectives, methods, timelines, and evaluation criteria. A literature review and complaint review are reactive and may not capture rare or long-term failures of a novel coating. The 2-year study with 50 patients is underpowered and too short for a 10-year implant; revision rate at 2 years is not a reliable surrogate for long-term survival. The plan also lacks a clear hypothesis, sample size justification, follow-up schedule, and analysis plan. For a Class III implant with a novel coating, the PMCF plan should be designed to detect device-related adverse events, coating wear or delamination, osteolysis, and revision. The notified body should require a revised plan before certification. The plan should be proportionate to the risk and the novelty of the device.
2. What should a PMCF plan include for this device?
Read the worked answer
The PMCF plan should include: (1) a clear objective, e.g., to confirm long-term safety and performance and to detect coating-related failures; (2) the target population and sample size, justified by the expected revision rate and the precision required; (3) endpoints such as implant survival, revision for any cause, radiographic evidence of osteolysis or coating delamination, adverse events, and patient-reported outcomes; (4) a follow-up schedule of at least 5-10 years, with interim analyses; (5) use of independent registries and/or a prospective cohort, with a control or comparator; (6) data management, monitoring, and statistical analysis; (7) a schedule for PMCF evaluation reports; and (8) a process for feeding findings into the risk management file and technical documentation. The plan should also address the novelty of the coating and the potential for delayed failures. A 2-year study can be part of the plan but cannot be the sole source of long-term evidence.
3. How should the PSUR and vigilance data feed into the PMCF and risk management?
Read the worked answer
Under MDR Article 86, a Class III device requires an annual PSUR. The PSUR must summarise the results of the PMS plan, including vigilance data, complaints, and PMCF. Vigilance reports, serious incidents, and field safety corrective actions must be analysed for trends and root causes. These data should feed into the risk management file under ISO 14971 Clause 10 (production and post-production activities). If a trend or a serious incident signals a new hazard, the manufacturer must update the risk assessment and consider changes to the PMCF plan, the instructions for use, or the device design. The PMCF evaluation report and the PSUR should be consistent; discrepancies must be explained. The notified body should verify that the manufacturer has a closed-loop system: PMS/vigilance - risk management - PMCF - updated clinical evaluation. Without that loop, the PMCF plan is not effective.